Literature DB >> 28245151

Lung Cancers Manifesting as Part-Solid Nodules in the National Lung Screening Trial.

Rowena Yip1, Claudia I Henschke1, Dong Ming Xu1, Kunwei Li1,2, Artit Jirapatnakul1, David F Yankelevitz1.   

Abstract

OBJECTIVE: The objective of our study was to determine how often death occurred from lung cancers that manifested as part-solid nodules in the National Lung Screening Trial (NLST).
MATERIALS AND METHODS: NLST radiologists classified nodules as solid, ground-glass, or mixed. All lung cancers classified as mixed nodules by NLST radiologists were reviewed by four experienced radiologists and reclassified as solid, nonsolid, or part-solid nodules. When possible, volume doubling times (VDTs) were calculated separately for the entire nodule and for the solid component of the nodule.
RESULTS: Of 88 screening-diagnosed lung cancer cases identified by the NLST radiologists as mixed nodules, study radiologists confirmed that 19 were part-solid nodules. All the part-solid nodules were present at baseline (time 0), and none of the patients with a part-solid nodule had lymph node enlargement at CT before diagnosis or metastases at resection. Multilobar stage IV (T4N0M1) bronchioloalveolar carcinoma was diagnosed in one patient 25.0 months after study randomization, and the patient died 67.9 months after randomization. All 18 patients with a solitary or dominant part-solid nodule underwent surgery, and none died of lung cancer. From randomization, the average time to diagnosis was 18.6 months and the average time of follow-up was 79.2 months. On the last CT examination performed before diagnosis, the average size of the solid component of the part-solid nodules was 9.2 mm (SD, 4.9); the solid component was larger than 10 mm in five patients. The median VDT based on the entire nodule was 476 days, and the median VDT based on the solid component alone was 240 days.
CONCLUSION: None of the patients with lung cancer manifesting as a solitary or dominant part-solid nodule had lymph node enlargement or metastases at pathology, and none died of lung cancer within the follow-up time of the NLST.

Entities:  

Keywords:  CT screening; growth rates; subsolid nodules; survival; volume doubling times

Mesh:

Year:  2017        PMID: 28245151     DOI: 10.2214/AJR.16.16930

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  8 in total

1.  CT diagnosis of pleural and stromal invasion in malignant subpleural pure ground-glass nodules: an exploratory study.

Authors:  Qing Zhao; Jian-Wei Wang; Lin Yang; Li-Yan Xue; Wen-Wen Lu
Journal:  Eur Radiol       Date:  2018-06-25       Impact factor: 5.315

2.  The natural course of incidentally detected, small, subsolid lung nodules-is follow-up needed beyond current guideline recommendations?

Authors:  Benedikt H Heidinger; Mario Silva; Constance de Margerie-Mellon; Paul A VanderLaan; Alexander A Bankier
Journal:  Transl Lung Cancer Res       Date:  2019-12

3.  An Intervention to Tag Findings Suspicious for Lung Cancer on Chest Computed Tomography Has Good Sensitivity and Number Needed to Diagnose.

Authors:  Jennifer R Dusendang; Lori C Sakoda; Thomas H Urbania; Sora Ely; Todd Osinski; Ashish Patel; Lisa J Herrinton
Journal:  Perm J       Date:  2021-05-12

Review 4.  Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Douglas E Wood; Ella A Kazerooni; Scott L Baum; George A Eapen; David S Ettinger; Lifang Hou; David M Jackman; Donald Klippenstein; Rohit Kumar; Rudy P Lackner; Lorriana E Leard; Inga T Lennes; Ann N C Leung; Samir S Makani; Pierre P Massion; Peter Mazzone; Robert E Merritt; Bryan F Meyers; David E Midthun; Sudhakar Pipavath; Christie Pratt; Chakravarthy Reddy; Mary E Reid; Arnold J Rotter; Peter B Sachs; Matthew B Schabath; Mark L Schiebler; Betty C Tong; William D Travis; Benjamin Wei; Stephen C Yang; Kristina M Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2018-04       Impact factor: 11.908

5.  Multiomics Analysis Reveals Distinct Immunogenomic Features of Lung Cancer with Ground-Glass Opacity.

Authors:  Kezhong Chen; Jing Bai; Alexandre Reuben; Heng Zhao; Guannan Kang; Chunliu Zhang; Qingyi Qi; Yaping Xu; Shawna Hubert; Lianpeng Chang; Yanfang Guan; Lin Feng; Kai Zhang; Kaitai Zhang; Xin Yi; Xuefeng Xia; Shujun Cheng; Fan Yang; Jianjun Zhang; Jun Wang
Journal:  Am J Respir Crit Care Med       Date:  2021-11-15       Impact factor: 21.405

6.  From focal pulmonary pure ground-glass opacity nodule detected by low-dose computed tomography into invasive lung adenocarcinoma: A growth pattern analysis in the elderly.

Authors:  Xin Nie; Lin Li; Juan Huang; Ping Zhang; Hong Shi; Gang Cheng; Yong-Qiang Zhang
Journal:  Thorac Cancer       Date:  2018-08-24       Impact factor: 3.500

7.  Comprehensive Study of Surgical Treated Lung Adenocarcinoma with Ground Glass Nodule Component.

Authors:  Ye Xu; Min Zheng; Ning Wang; Rui Wang
Journal:  Med Sci Monit       Date:  2019-11-11

8.  The Regimen of Computed Tomography Screening for Lung Cancer: Lessons Learned Over 25 Years From the International Early Lung Cancer Action Program.

Authors:  Claudia I Henschke; Rowena Yip; Dorith Shaham; Javier J Zulueta; Samuel M Aguayo; Anthony P Reeves; Artit Jirapatnakul; Ricardo Avila; Drew Moghanaki; David F Yankelevitz
Journal:  J Thorac Imaging       Date:  2021-01       Impact factor: 5.528

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.